Caspian Therapeutics, Kura Oncology Plan To Devise Development Strategy For Caspian's KO-7246 Oral Menin Inhibitor Designed For Diabetes And Other Chronic Metabolic Diseases
Caspian Therapeutics, Inc. ("Caspian") and Kura Oncology, Inc. (Nasdaq: KURA, "Kura") plan to outline the development strategy for KO-7246, Caspian’s selective, oral menin inhibitor designed for diabetes
Two drug companies are teaming up to develop a new medicine for diabetes. When companies partner on medicine development, it shows they believe in the project's future.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.